Patients who develop CAR T cell-related HLH–MAS can be treated simultaneously with anti-IL-6 therapy and corticosteroids (Fig. 1); responses to anti-IL-6 therapy alone might not be as common as in patients with CRS alone33. Here, IL6 is linked to congenital rubella syndrome.